地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771149750
传真:18771997407
邮箱:sales@amyjet.com

艾美捷科技代理Diaclone品牌检测试剂。
Diaclone是一家集酶联免疫试剂盒、流式抗体为一体的公司,在炎症、肿瘤、免疫学领域深耕多年;ELISA 试剂盒可对细胞因子、趋化因子、 生长因子进行有效检测。Diaclone的产品线主要包括:细胞因子和细胞黏附分子的抗体:这些抗体被广泛应用于酶联免疫检测试剂盒中,用于检测和量化细胞因子和细胞黏附分子的表达水平。酶联免疫试剂盒(ELISA):Diaclone提供多种规格和型号的ELISA试剂盒,用于检测各种生物样本中的特定抗原或抗体。这些试剂盒具有灵敏度高、特异性强、操作简便等特点。酶联免疫斑点检测试剂盒(ELISpot):ELISpot技术是一种用于检测细胞分泌特定蛋白质(如细胞因子)的灵敏方法。Diaclone的ELISpot试剂盒可用于研究细胞免疫应答,如T细胞活性等。
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Diaclone品牌检测试剂"> 艾美捷科技代理Diaclone品牌检测试剂

Kalen Biomedical为全世界范围内的心血管研究机构提供一流品质的脂蛋白(lipoprotein)。通过制定严格的生产流程和高标准的质控体系,Kalen Biomedical能够保证产品品质的持续稳定性。Kalen Biomedical的产品线包括天然的人类脂蛋白,氧化和乙酰化的低密度脂蛋白,此外还有脂蛋白探针、脂蛋白缺失血清和培养基。
Kalen Biomedical, LLC provides premium quality lipoproteins for the international cardiovascular research community. Kalen has developed stringent manufacturing procedures and Quality Control to ensure our products perform consistently.
Kalen’s lipoprotein product line includes native human lipoproteins and oxidized and acetylated Low Density Lipoproteins (LDL). Our lipoprotein probes offer the convenience of fluorescence or biotin labeled LDL. We supply lipoprotein depleted serum media supplement for specialized cell cultures (shipment to North America only).
Kalen Biomedical的主要产品包括:
Native Lipoproteins
Acetylated Lipoproteins
Oxidized Lipoproteins
Labeled Lipoproteins
Lipoprotein Depleted Sera
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
< " data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Kalen Biomedical"> Kalen Biomedical
艾美捷科技有限公司代理SIRIUS FINE CHEMICALS SICHEM GMBH公司产品。
SIRIUS FINE CHEMICALS SICHEM GMBH公司,主要提供:
点击化学工具(Si-CLICK (Click Chemistry))
PEG试剂(Si-PEGs)
脂质及其衍生物(Si-LIPs (Lipids & Derivatives))
磷酸肌醇试剂(Inositol Phosphates & Phosphoinositides)
核酸及其衍生物(Nucleotides & Derivatives)
API标准品及代谢底物(API Standards & Metabolites)
稳定的同位素(Stable Isotopes)
磷酸化及亚磷酸化试剂(Phosphorylation / Phosphitylation)
精细化学试剂(Fine Chemicals)
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
产品列表
| 产品名称 | 产品编号 | 分子式 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4/EQ) / EQUATORIAL isomer | SC-8060 | C15H26N2O4 |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Click Amino Acid / exo-BCN – Fmoc – L - Lysine (BCN) | SC-8038 | C32H36N2O6 |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| Click-Amino-Acid / N3-Lys | SC-8027 | C9H17N5O4 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |
| Click Amino Acid / endo-BCN – Fmoc – L - Lysine (BCN) | SC-8015 | C32H36N2O6 |
| Click Amino Acid / trans-Cyclooct-2-en – L - Lysine (TCO*A) | SC-8008 | C15H26N2O4 |
| Click Amino Acid / exo BCN - L - Lysine | SC-8016 | C17H26N2O4 |
| Click Amino Acid / Norbonene-CH2 – L - Lysine (NBO) | SC-8006 | C15 H24 N2 O4 * HCl |
| Click Amino Acid / rac BCN - L - Lysine | SC-8003 | C17H26N2O4 |
| Click Amino Acid / trans-Cyclooct-4-en – L - Lysine (TCO4) / AXIAL isomer | SC-8004 | C15H26N2O4 |
| Click Amino Acid / endo BCN - L - Lysine | SC-8014 | C17H26N2O4 |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Click Amino Acid (99%) / SCO - L - Lysine - HCO2H-salt | SC-8001 | C15H24N2O4* HCO2H |
| Click Amino Acid (95%) / SCO - L - Lysine - HCO2H-salt | SC-8000 | C15H24N2O4 * HCO2H |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| exo-BCN-NHS carbonate | SC-8075 | C15H17NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| exo BCN - OH | SC-8033 | C10 H14 O |
| SCO - active ester (p-NPE) | SC-8032 | C15H15NO5 |
| SCO - OH | SC-8030 | C8H12O |
| endo BCN - OH | SC-8029 | C10 H14 O |
| exo BCN - active ester (p-NPE) | SC-8010 | C17H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| (E)-cyclooct-4-enol / axial - TCO4 / A | SC-8018 | C8H14O |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| (E)-cyclooct-4-en active ester / TCO/E- active ester (p-NPE) / equatorial | SC-8024 | C15H17NO5 |
| (E)-cyclooct-4-en active ester / TCO4 / A- active ester (p-NPE) / axial | SC-8019 | C15H17NO5 |
| TCO*A - active ester (p-NPE) | SC-8007 | C15H17NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Aminopentyl - Tetrazine - HCl-salt | SC-1193 | C18H20N8O * HCl |
| Tetrazine active ester (Tetrazine-NHS) | SC-1194 | C17H11N7O4 |
| Aminopropyl - Tetrazine - HCl-salt | SC-1192 | C16H16N8O * HCl |
| Methyl-Tetrazine - Amine- HCO2H-salt | SC-1191 | C10H11N5* HCO2H |
| Tetrazine - Amine - HCO2H-salt | SC-1190 | C9H9N5 * HCO2H |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Click-Amino-Acid / PrK - HCl-salt | SC-8002 | C10H16N2O4 * HCl |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| Bis-Cyano-PEG9 | SC-8932 | C22H40N2O9 |
| Bis-Cyano-PEG5 | SC-8931 | C14H24N2O5 |
| Bis-Cyano-PEG4 | SC-8930 | C12H20N2O4 |
| N3-PEG8-t-butyl ester | SC-8923 | C23H45N3O10 |
| N3-PEG5-t-butyl ester | SC-8922 | C17H33N3O7 |
| N3-PEG4-t-butyl ester | SC-8921 | C15H29N3O6 |
| N3-PEG3-t-butyl ester | SC-8920 | C13H25N3O5 |
| Boc-N-Amido-PEG7-N3 | SC-8912 | C21H42N4O9 |
| Boc-N-Amido-PEG3-N3 | SC-8911 | C13H26N4O5 |
| Boc-N-Amido-PEG2-N3 | SC-8910 | C11H22N4O4 |
| Boc-N-Amido-PEG4-Alkyne | SC-8900 | C16H29NO6 |
| Boc-N-Amido-PEG3-Alkyne | SC-8039 | C14H25NO5 |
| Fluorescent-PEG8-Me-Tet | SC-8817 | C54H68N8O13 |
| Fluorescent-PEG4-Me-Tet | SC-8816 | C46H52N8O9 |
| Fluorescent-PEG3-Me-Tet | SC-8815 | C44H48N8O8 |
| TAMRA-PEG8-Alkyne | SC-8717 | C44H57N3O12 |
| TAMRA-PEG4-Alkyne | SC-8716 | C36H41N3O8 |
| TAMRA-PEG3-Alkyne | SC-8715 | C34H37N3O7 |
| TAMRA-PEG7-N3 | SC-8714 | C41H54N6O11 |
| TAMRA-PEG3-N3 | SC-8713 | C33H38N6O7 |
| TAMRA-PEG2-N3 | SC-8712 | C31H34N6O6 |
| TAMRA-PEG8-COOH | SC-8711 | C44H59N3O14 |
| TAMRA-PEG4-COOH | SC-8710 | C36H43N3O10 |
| TAMRA-PEG3-COOH | SC-8709 | C34H39N3O9 |
| TAMRA-PEG8-NHS | SC-8708 | C48H62N4O16 |
| TAMRA-PEG4-NHS | SC-8707 | C40H46N4O12 |
| TAMRA-PEG3-NHS | SC-8706 | C38H42N4O11 |
| TAMRA-PEG7-Maleimide | SC-8705 | C48H61N5O14 |
| TAMRA-PEG3-Maleimide | SC-8704 | C40H45N5O10 |
| TAMRA-PEG2-Maleimide | SC-8703 | C38H41N5O9 |
| TAMRA-PEG7-NH2 | SC-8702 | C41H56N4O11 |
| TAMRA-PEG3-NH2 | SC-8701 | C33H40N4O7 |
| TAMRA-PEG2-NH2 | SC-8700 | C31H36N4O6 |
| Me-Tet-PEG8-NHBoc | SC-8820 | C34H56N6O11 |
| Me-Tet-PEG4-NHBoc | SC-8819 | C26H40N6O7 |
| Me-Tet-PEG3-NHBoc | SC-8818 | C24H36N6O6 |
| Biotin-PEG8-Me-Tet | SC-8814 | C39H62N8O11S |
| Biotin-PEG4-Me-Tet | SC-8813 | C31H46N8O7S |
| Biotin-PEG3-Me-Tet | SC-8812 | C29H42N8O6S |
| Me-Tet-PEG9-COOH | SC-8811 | C32H51N5O12 |
| Me-Tet-PEG5-COOH | SC-8810 | C24H35N5O8 |
| Me-Tet-PEG4-COOH | SC-8809 | C22H31N5O7 |
| Me-Tet-PEG9-NHS | SC-8808 | C36H54N6O14 |
| Me-Tet-PEG5-NHS | SC-8807 | C28H38N6O10 |
| Me-Tet-PEG4-NHS | SC-8806 | C26H34N6O9 |
| Me-Tet-PEG8-Maleimide | SC-8805 | C36H53N7O12 |
| Me-Tet-PEG4-Maleimide | SC-8804 | C28H37N7O8 |
| Me-Tet-PEG3-Maleimide | SC-8803 | C26H33N7O7 |
| Me-Tet-PEG8-NH2 - HCl salt | SC-8802 | C29H48N6O9 + HCl |
| Me-Tet-PEG4-NH2 | SC-8801 | C21H32N6O5 |
| Me-Tet-PEG3-NH2 | SC-8800 | C19H28N6O4 |
| Biotin-PEG8-Alkyne | SC-8617 | C29H51N3O10S |
| Biotin-PEG4-Alkyne | SC-8616 | C21H35N3O6S |
| Biotin-PEG3-Alkyne | SC-8615 | C19H31N3O5S |
| Biotin-PEG7-N3 | SC-8614 | C26H48N6O9S |
| Biotin-PEG3-N3 | SC-8613 | C18H32N6O5S |
| Biotin-PEG2-N3 | SC-8612 | C16H28N6O4S |
| Biotin-PEG8-COOH | SC-8611 | C29H53N3O12S |
| Biotin-PEG4-COOH | SC-8610 | C19H33N3O7S |
| Biotin-PEG3-COOH | SC-8609 | C19H33N3O7S |
| Biotin-PEG8-NHS | SC-8608 | C33H56N4O14S |
| Biotin-PEG4-NHS | SC-8607 | C25H40N4O10S |
| Biotin-PEG3-NHS | SC-8606 | C23H36N4O9S |
| Biotin-PEG7-Maleimide | SC-8605 | C33H55N5O12S |
| Biotin-PEG3-Maleimide | SC-8604 | C25H39N5O8S |
| Biotin-PEG2-Maleimide | SC-8603 | C23H35N5O7S |
| Biotin-PEG7-NH2 | SC-8602 | C26H50N4O9S |
| Biotin-PEG3-NH2 | SC-8601 | C18H34N4O5S |
| Biotin-PEG2-NH2 | SC-8600 | C16H30N4O4S |
| TCO4-PEG8-COOH | SC-8411 | C28H51NO12 |
| TCO*-PEG8-COOH | SC-8511 | C28H51NO12 |
| TCO*-PEG4-COOH | SC-8510 | C20H35NO8 |
| TCO4-PEG4-COOH | SC-8410 | C20H35NO8 |
| TCO4-PEG3-COOH | SC-8409 | C18H31NO7 |
| TCO*-PEG3-COOH | SC-8509 | C20H31NO7 |
| TCO*-PEG8-NHS | SC-8508 | C32H54N2O14 |
| TCO4-PEG8-NHS | SC-8408 | C32H54N2O14 |
| TCO4-PEG4-NHS | SC-8407 | C24H38N2O10 |
| TCO*-PEG4-NHS | SC-8507 | C24H38N2O10 |
| TCO*-PEG3-NHS | SC-8506 | C22H34N2O9 |
| TCO4-PEG3-NHS | SC-8406 | C22H34N2O9 |
| TCO*-PEG7-Maleimide | SC-8505 | C32H53N3O12 |
| TCO*-PEG3-Maleimide | SC-8504 | C24H37N3O8 |
| TCO*-PEG2-Maleimide | SC-8503 | C22H33N3O7 |
| TCO4-PEG7-Maleimide | SC-8405 | C32H53N3O12 |
| TCO4-PEG3-Maleimide | SC-8404 | C24H37N3O8 |
| TCO4-PEG2-Maleimide | SC-8403 | C22H33N3O7 |
| TCO*-PEG2-NH2 | SC-8500 | C15H28N2O4 |
| TCO*-PEG3-NH2 | SC-8501 | C17H32N2O5 |
| TCO*-PEG7-NH2 | SC-8502 | C25H48N2O9 |
| TCO4-PEG7-NH2 | SC-8402 | C25H48N2O9 |
| TCO4-PEG3-NH2 | SC-8401 | C17H32N2O5 |
| TCO4-PEG2-NH2 | SC-8400 | C15H28N2O4 |
| SCO-PEG7-Maleimide | SC-8305 | C32H51N3O12 |
| SCO-PEG3-Maleimide | SC-8304 | C24H35N3O8 |
| SCO-PEG2-Maleimide | SC-8303 | C22H31N3O7 |
| BCN-exo-PEG7-Maleimide | SC-8205 | C34H53N3O12 |
| BCN-exo-PEG3-Maleimide | SC-8204 | C24H33N3O7 |
| BCN-exo-PEG2-Maleimide | SC-8203 | C24H33N3O7 |
| BCN-endo-PEG7-Maleimide | SC-8105 | C34H53N3O12 |
| BCN-endo-PEG3-Maleimide | SC-8104 | C24H33N3O7 |
| BCN-endo-PEG2-Maleimide | SC-8103 | C24H33N3O7 |
| BCN-exo-PEG8-COOH | SC-8211 | C30H51NO12 |
| BCN-exo-PEG4-COOH | SC-8210 | C22H35NO8 |
| BCN-exo-PEG3-COOH | SC-8209 | C20H31NO7 |
| BCN-exo-PEG8-NHS | SC-8208 | C34H54N2O14 |
| BCN-exo-PEG4-NHS | SC-8207 | C26H38N2O10 |
| BCN-exo-PEG3-NHS | SC-8206 | C24H34N2O9 |
| BCN-endo-PEG3-NHS | SC-8106 | C24H34N2O9 |
| BCN-endo-PEG4-NHS | SC-8107 | C26H38N2O10 |
| BCN-endo-PEG8-NHS | SC-8108 | C34H54N2O14 |
| BCN-endo-PEG8-COOH | SC-8111 | C30H51NO12 |
| BCN-endo-PEG4-COOH | SC-8110 | C22H35NO8 |
| BCN-endo-PEG3-COOH | SC-8109 | C20H31NO7 |
| SCO-PEG3-COOH | SC-8309 | C18H29NO7 |
| SCO-PEG4-COOH | SC-8310 | C20H33NO8 |
| SCO-PEG8-COOH | SC-8311 | C28H49NO12 |
| SCO-PEG8-NHS | SC-8308 | C32H52N2O14 |
| SCO-PEG4-NHS | SC-8307 | C24H36N2O10 |
| SCO-PEG3-NHS | SC-8306 | C22H32N2O9 |
| SCO-PEG7-NH2 | SC-8302 | C25H46N2O9 |
| SCO-PEG3-NH2 | SC-8301 | C17H30N2O5 |
| SCO-PEG2-NH2 | SC-8300 | C15H26N2O4 |
| BCN-exo-PEG2-NH2 | SC-8200 | C17H28N2O4 |
| BCN-exo-PEG3-NH2 | SC-8201 | C19H32N2O5 |
| BCN-exo-PEG7-NH2 | SC-8202 | C27H48N2O9 |
| BCN-endo-PEG7-NH2 | SC-8102 | C27H48N2O9 |
| BCN-endo-PEG3-NH2 | SC-8101 | C19H32N2O5 |
| BCN-endo-PEG2-NH2 | SC-8100 | C17H28N2O4 |
| PEG-12 | SC-1512 | C24H50O13 |
| PEG-11 | SC-1511 | C22H46O12 |
| PEG-10 | SC-1510 | C20H42O11 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Alkyne - PEG2 - TCA | SC-0067 | C9H12Cl3NO3 |
| Azido - PEG2 - TCA | SC-0066 | C6H9Cl3N4O2 |
| Alkyne - PEG2 - CM | SC-0065 | C8H13ClO3 |
| Azido - PEG2 - CM | SC-0064 | C5H10ClN3O |
| Alkyne - PEG2 | SC-0063 | C7H12O3 |
| Azido - PEG1 | SC-0062 | C4H9N3O2 |
| 2-Methyl-Glycerol | SC-0006 | C4H10O3 |
| 2-Stearoyl glycerol | SC-1171 | C21H42O4 |
| 2-Palmitoyl glycerol | SC-1170 | C19H38O4 |
| 2-Myristoyl glycerol | SC-1169 | C17H34O4 |
| 2-Lauroyl glycerol | SC-1168 | C15H30O4 |
| 2-Linoleoyl glycerol | SC-1167 | C21H38O4 |
| 2-Oleoyl-glycerol | SC-1162 | C21H40O4 |
| SH-6 | SC-0045 | C28H57O9P |
| SH-5 | SC-0044 | C29H59O10P |
| Ins(345)P3*3Na | 3-0-345-Na | C6H12Na3O15P3 |
| Ins(1)P*2K | 1-0-1-2K | C6H11K2O9P |
| myo-Inositol – trispyrophosphate | Pyro-Ins-Na | C6H8Na4O21P6 |
| Ins(123456)P6 | 6-0-123456-Na | C6H18O24P6 * xNa*yH2O |
| Ins(23456)P5*10Na | 5-0-23456-Na | C6H7Na10O21P5 |
| Ins(13456)P5*10Na | 5-0-13456-Na | C6H7Na10O21P5 |
| Ins(12456)P5*10Na | 5-0-12456-Na | C6H7Na10O21P5 |
| Ins(12356)P5*10Na | 5-0-12356-Na | C6H7Na10O21P5 |
| Ins(12345)P5*10Na | 5-0-12345-Na | C6H7Na10O21P5 |
| Ins(1345)P4*8Na | 4-0-1345-Na | C6H8Na8O18P4 |
| Ins(136)P3*6Na | 3-0-136-Na | C6H9Na6O15P3 |
| Ins(134)P3*6K | 3-0-134-K | C6H9K6O15P3 |
| Ins(345)P3*3K | 3-0-345-K | C6H12K3O15P3 |
| Ins(145)P3*6K | 3-0-145-K | C6H9K6O15P3 |
| Ins(145)P3*3Li | 3-0-145-Li | C6H12Li3O15P3 |
| Ins(145)P3*6Na | 3-0-145-Na | C6H9Na6O15P3 |
| Ins(135)P3*6Na | 3-0-135-6Na | C6H9Na6O15P3 |
| Ins(1245)P4*8Na | 4-0-1245-Na | C6H8Na8O18P4 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Bt3-Ins(356)P3 / PM | 3-2-356 | C42H69O30P3 |
| Bt3-Ins(346)P3 / PM | 3-2-346 | C42H69O30P3 |
| Bt3-Ins(146)P3 / PM | 3-2-146 | C42H69O30P3 |
| Bt3-Ins(135)P3 / PM | 3-2-135 | C42H69O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| Bt2-Ins(3456)P4 / PM | 4-2-3456 | C46H76O36P4 |
| Bt2-Ins(1456)P4 / PM | 4-2-1456 | C46H76O36P4 |
| Bt2-Ins(1345)P4 / PM | 4-2-1345 | C46H76O36P4 |
| Bt2-Ins(1356)P4 / AM | 4-1-1356 | C38H60O36P4 |
| Bt3-Ins(356)P3 / AM | 3-1-356 | C36H57O30P3 |
| Bt3-Ins(346)P3 / AM | 3-1-346 | C36H57O30P3 |
| Bt3-Ins(146)P3 / AM | 3-1-146 | C36H57O30P3 |
| Bt3-Ins(134)P3 / AM | 3-1-134 | C36H57O30P3 |
| Bt3-Ins(136)P3 / AM | 3-1-136 | C36H57O30P3 |
| Bt3-Ins(135)P3 / AM | 3-1-135 | C36H57O30P3 |
| Bt3-Ins(145)P3 / AM | 3-1-145 | C36H57O30P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-10 | C42H64NO31P3 |
| caged-Ins(145)P3 / PM | cag-iso-2-145-100 | C42H64NO31P3 |
| caged-Ins(145)P3O6 | cag-6-145 | C15H18NO19P3Na6 |
| caged-Ins(145)P3 P4 | cag-0-145 | C14H19NO17P3Na3 |
| PtdIns(345)P3 | Ptd-0-345-16 | C41H82O22P4 |
| PtdIns(45)P2 | Ptd-0-45-16 | C41H81O19P3 |
| PtdIns(34)P2 | Ptd-0-34-16 | C41H81O19P3 |
| PtdIns(5)P | Ptd-0-5-16 | C41H80O16P2 |
| PtdIns(4)P | Ptd-0-4-16 | C41H80O16P2 |
| PtdIns(3)P | Ptd-0-3-16 | C41H80O16P2 |
| PtdIns(1)P | Ptd-0-1-16 | C41H79O13P |
| D-myo-Inositol-1,2-O-cyclohexylidene | SC-0088 | C12H20O6 |
| 23:45- diisopropylidene-myo-Inositol | SC-0079 | C12H20O6 |
| 12:56- diisopropylidene-myo-Inositol | SC-0078 | C12H20O6 |
| D-myo-Inositol-2,3-O-cyclohexylidene | SC-0077 | C12H20O6 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| 2,3:4,5-Di-O-Iso-1,6-Di-O-Benzyl-Ins | IOB-Ins-2345 | C26H32O6 |
| 1,2:5,6-Di-O-Iso-3,4-Di-O-Benzyl-Ins | IOB-Ins-1256 | C26H32O6 |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| DEAC-dUTP | SC-9002 | C26H31N4O17P3 |
| 35-PAPS-TEA | SC-9000-TEA | C10H15N5O13P2S x 4 C6 H15 N |
| ACPPS-TEA | SC-0068 | C10H13N5O12P2S + C6H5N |
| 25-PAPS-Li | SC-9001-Li | C10H11Li4N5O13P2S |
| 35-PAPS-Li (CAS: 102029-54-9) | SC-9000-Li | C10H11Li4N5O13P2S |
| EdU | SC-0040 | C11H12N2O5 |
| EdUTP-TEA | SC-0039 | C11H15N2O14P3 * 4(C6H15N) |
| EdUTP | SC-0038 | C11H15N2O14P3 |
| 2'-PAP | SC-0037 | C10H17N5O10P2 |
| 2'-PAP-Na | SC-0036 | C10H15N5Na2O10P2 |
| 3'-PAP-Na | SC-0034 | C10H15N5Na2O10P2 |
| 3'-PAP | SC-0035 | C10H17N5O10P2 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Didechloro Vancomycin | SC-1605 | C66H77N9O24 |
| Vancomycin Impurity A | SC-1601 | C65H73Cl2N9O24 |
| Vancomycin Impurity D | SC-1604 | C59H62Cl2N8O22 |
| Vancomycin Impurity C | SC-1603 | C53H52Cl2N8O17 |
| Vancomycin Impurity B | SC-1602 | C66H74Cl2N8O25 |
| INO-4995 | INO-4995 | C50H86O35P4 |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Podophyllotoxin Derivate | SC-0025 | C21H20O8 |
| Podophyllotoxin Derivate | SC-0026 | C21H21NO7 |
| Clopidogrel Impurity 4 | SC-0099 | C16H16ClNO2S * H2SO4 |
| Gestodene Impurity E | SC-0028 | C21H24O3 |
| Fidaxomicin Metabolite OP-1118 | SC-1158 | C48H68Cl2O17 |
| Prasugrel metabolite M6-d3 (stabilzed) | SC-0093 | C27H25D3FNO5S * HCl |
| Prasugrel metabolite M6 | SC-0092 | C19H22FNO3S |
| Clopidogrel Impurity C | SC-0087 | C16H18ClNO2S |
| Clopidogrel Impurity 3 | SC-0086 | C15H17Cl2NO2S |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| Prasugrel active metabolite M3 HCl (stabilized) | SC-0029 | C27H28FNO5S * HCl |
| Fidaxomicin - d7 | SC-1157 | C52H67D7Cl2O18 |
| Methyl 4-(2-hydroxyethyl)benzoate-13C6,2D (Ring-13C6,Ethyl-1,2-D2) | SC-0080 | C4 13C6 H10 D2 O3 |
| Anthracene 13C6 | SC-0074 | 13C6C8H8 |
| Phenanthrene 13C6 | SC-0073 | 13C6C8H8 |
| Naphthalene 13C10 | SC-0072 | 13C10H8 |
| Naphthalene 13C6 | SC-0071 | 13C6C4H8 |
| Prasugrel active metabolite M3-d3 (stabilzed) | SC-0033 | C27H25D3FNO5S * HCl |
| 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite | SC-0091 | C9H18ClN2OP |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(2-cyanoethyl) ester | SC-0061 | C12H22N3O2P |
| Phosphoramidous acid, N,N-bis(1-methylethyl)-, bis(phenylmethyl) ester | SC-1165 | C20 H28 N O2 P |
| Phosphorodiamidous acid. N.N.N'.N'-tetrakis(1-methylethyl)-. phenylmethyl ester | SC-0060 | C19 H35 N2 O P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. 2-cyanoethyl [1-(2-nitrophenyl)ethyl] ester) | SC-0059 | C17 H26 N3 O4 P |
| Dichloro N,N-Diisopropylphosphoramidite | SC-0058 | C6 H14 Cl2 N P |
| Phosphoramidous acid. N.N-bis(1-methylethyl)-. bis(9H-fluoren-9-ylmethyl) ester | SC-0057 | C34 H36 N O2 P |
| Di-tert-butyl chloromethyl phosphate | SC-0011 | C9H20ClO4P |
| Di-benzyl chloromethyl phosphate | SC-0010 | C15H16ClO4P |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| D-Serine-O-phosphate | SC-1810 | C3H8NO6P |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Menaquinone 8 / MK 8:8 | SC-1230 | C51H72O2 |
| Allyl-Maleimide | SC-1121 | C7H7NO2 |
| Nor-cisapride Derivative | SC-1161 | C17H25Cl2N3O3 |
| AlK - L - Lysine - HCl-salt | SC-8012 | C10H18N2O4* HCl |
| 4-methyl-2,2-bis(trifluoromethyl)oxazolidin-5-one | SC-0098 | C6H5F6NO2 |
| 3-(5-oxo-2,2-bis(trifluoromethyl)oxazolidin-4-yl)propanoic acid | SC-0097 | C8H7F6NO4 |
| 7-(diethylamino)-4-(hydroxymethyl)-coumarin / DEACM | SC-0096 | C14H17NO3 |
| 3-bromo-4-methyl-7-(diethylamino)-coumarin | SC-0095 | C14H16BrNO2 |
| Xanthohumol | SC-0094 | C21H22O5 |
| IEPOX 4 | SC-0090 | C5H10O3 |
| IEPOX 3 | SC-0089 | C5H10O3 |
| 2-C-Methyl-L-Threitol | SC-0085 | C5H12O4 |
| 2-C-Methyl-D-Threitol | SC-0084 | C5H12O4 |
| 2-C-Methyl-L-Erythritol | SC-0083 | C5H12O4 |
| 2-C-Methyl-D-Erythritol | SC-0082 | C5H12O4 |
| 3-Amino-7-(diethylamino)-coumarine | SC-0081 | C13 H16 N2 O2 |
| Chloromethylpropionate | SC-1164 | C4H7ClO2 |
| 2-(2-fluoro-2-methylpropoxy)-2-methylpropan-1-ol | SC-1163 | C8H17FO2 |
| 1,4-Di-butyryl-23:56-diisopropylidene-myo-Inositol | SC-0076 | C20H32O8 |
| 3,6-Di-butyryl-12:45-diisopropylidene-myo-Inositol | SC-0075 | C20H32O8 |
| Y-27632 | SC-0048 | C14H21N3O *2HCl |
| H-1152 | SC-0053 | C16H21N3O2S*2HCl |
| 3,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-3456 | C34H36O6 |
| 1,4,5,6-Tetra-O-Benzyl-Ins | TOB-Ins-1456 | C34H36O6 |
| Biotin-PEG3-CoenzymeA | SC-8618 | C46H75N12O24P3S2+3NH3 |
| TMe-OHB-DAZA | SC-0300 | C29H37N3O6 |
| TEt-OHB-DAZA | SC-0301 | C32H43N3O6 |
| SCO-NHS carbonate | SC-8076 | C13H15NO5 |
| endo-BCN-NHS carbonate | SC-8074 | C15H17NO5 |
| TCO4 - NHS carbonate / EQUATORIAL isomer | SC-8073 | C13H17NO5 |
| TCO4 - NHS carbonate / AXIAL isomer | SC-8072 | C13H17NO5 |
| TCO* - NHS carbonate / EQUATORIAL isomer | SC-8071 | C13H17NO5 |
| TCO* - NHS carbonate / AXIAL isomer | SC-8070 | C13H17NO5 |
| NEmo2E | SC-0201 | C96H138KN18O30S |
| NEmo1 | SC-0200 | C96H138KN18O30S |
| bifunctional Cross-Linking-Amino-Acid / PrDiAzK | SC-8028 | C13H20N4O5 |
| Vancomycin hexapeptide | SC-1606 | C59H62Cl2N8O23 |
| Ph-CCA-NH2 | SC-1400 | C16H12N2O |
| Cross-Linking-Amino-Acid / DiAzK | SC-8034 | C11H20N4O4 |
| PEG-9 | SC-1509 | C18H38O10 |
| PEG-8 | SC-1508 | C16H34O9 |
| Click Amino Acid / cyclopropene – L - Lysine (CP) | SC-8017 | C12H20N2O4 |

ApexBio Technology LLC 在生物研究肽和实验室试剂中首屈一指。ApexBio在许多研究领域都具有广泛的产品线,例如:遗传学,细胞凋亡,肿瘤生物学等。ApexBio还提供各种定制服务,包括肽的合成,抗体的产生和发展分析。
ApexBio is a premier provider of peptides and lab reagents for biological research. We carry a broad product line in research areas such as Apoptosis, Epigenetics, Cancer Biology and so on. Apexbio also provides custom services including peptide synthesis, antibody production and assay development.
ApexBio的主要产品包括:
Drug Screening Library
Drug Screening Panel
DNA/RNA Prep Kit
Biotinylation Reagents
Biochemicals
Bioactive Peptides
Tag Peptides
Growth Factors
Amino Acids & Building Blocks
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="ApexBio"> ApexBio
Kord-Valmark隶属于Bioplast Manufacturing公司,是专业化的培养皿生产商。
Kord-Valmark Labware Products by Bioplast Manufacturing, L.L.C. is a leading manufacturer of quality petri dishes. Our technical knowledge, experience and manufacturing capabilities – along with our superior mold design, precise process control and rigorous quality programs – allow us to manufacture the highest-quality products. Kord-Valmark’s disposable dishes provide unrivaled consistency, ease of use and exceptional value.
Kord-Valmark公司主要产品:
(1)Stackable Petri Dishes
Stackable polystyrene petri dishes are recommended for standard microbiology and general laboratory use
The stackable lid design ensures stability
Optically clear top and bottom viewing surfaces
Consistent flatness allows for even media distribution
Available in 3 sizes: 60 x 15 mm, 100 x 15 mm, and 100 x 25 mm
(2)Automation Petri Dishes
Automation and Slippable polystyrene petri dishes are recommended for standard microbiology and general laboratory use
Slippable lids provide a semi-stacking feature for hand use, while ensuring ease of use in automated equipment
Automation lids have no rim, ensuring ease of use in automated equipment
Select products are available with Side Arrows and/or ISO Mark Targets
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
< " data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="KORD-Valmark"> KORD-Valmark
ProteinMods公司位于美国,是定制蛋白、抗体及生物化学分子产品的的供应商。
ProteinMods is a US based manufacter of custom proteins, antibodies and biomolecules. We strive to provide high quality and reliable products for your lab. ProteinMods is headed by Joe Beck, PhD. He is a versatile PhD. cell biologist with postdoctoral training in analytical chemistry and multiple years experience in drug development. Joe has a diverse background as evidenced by accomplishments in pharmacology, protein chemistry, neuroscience, surface chemistry, and nanotechnology. His mission is to lead a company in the production of top quality proteins and antibodies for researchers across the country and internationally. Joe also participates in many other ventures related to the biochemistry industry forging a path of research and has contributed as an author on many different publications.
PROTEINMODS的主要产品包括:
Antibody
Biosensing
Flow Cytometry
Fluorescent Microscopy
Immunodepletion
Immunohistochemistry
Immunoprecipitation
Protease Assays
Protein Crosslinking
Western Blotting
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Rieke Metal公司位于美国内布拉斯加州Lincoln市,制造有机卤化锌和聚3-烷基噻吩产品。Rieke Metal提供超过5000种有机金属构件模块及超过40000种精细化学品,并且能够提供定制生产服务。
From the Rieke Metals headquarters in Lincoln, Nebraska, we manufacture the broadest line of organozinc halides and poly-3-alkylthiophenes of any company in the world. We offer over 5,000 organometallic building blocks and over 40,000 fine chemicals with the ability to custom manufacture many more. The Rieke team has over 135 years of shared experience conducting inert atmosphere reactions. Our expertise in creating reliable organozinc and Grignard reagents, fine chemicals, semiconducting polymers is unmatched. It’s no surprise that Rieke Metals has been honored to serve many of the largest and most innovative pharmaceutical and electronics companies in the world.
Rieke Metals公司主要产品:
1000 - Rieke® Highly Reactive Metals
2000 - Rieke® Organozinc Reagents
3000 - Grignard Reagents
4000 - Rieke® Specialty Conducting Polymers
4100 - Substituted Thiophenes
5000 - Functionalized Benzophenones
5500 - Heterocyclic Ketones
6000 - Functionalized Ketones
6250 - Functionalized Benzoylacetonitriles
6500 - Functionalized Trifluoromethyl Ketones
7000 - Functionalized Ketoacids
7500 - Functionalized Ketoesters
8000 - Functionalized Aldehydes and Acetals
8500 - Functionalized Ketoacetals
9000 - 1-Keto-3-Protected Aldehydes
10000 - Functionalized Terminal Alkenes
11000 - Biphenyls (Heterocyclic, Bipyridines, and Pyridyl Phenylamines)
14000 - Alpha-Ketoesters and Acids
18000 - Cyclopentane Dicarboxylic Acids, Anydrides, Ester Acids, and Derivatives
18500 - Cyclohexane Dicarboxylic Acids, Anydrides, Ester Acids, and Derivatives
Novel Chemical Synthesis fine organic compounds
Novel Chemical Synthesis Grignard reagents
Novel Chemical Synthesis organozinc reagents
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Rieke Metals"> Rieke Metals
Innovative Research of America(IRA) 是一家致力研发于药物定量定时缓释系统的专业化公司,又称Matrix-Driven Delivery (MDD) 给药系统。该给药系统由一个可生物吸收的基质组成,含有定量可控的活性给药成分,可以以设定的剂量在一定时间范围内进行给药。
Since it is not easy to administer drugs and hormones orally to research animals, several delivery methods have been devised as alternatives. However, most scientists continue to labor with unreliable injectables to conduct their research.
Matrix-Driven Delivery (MDD) Pellet(MDD片剂)的优势
Saves time
Ready-to-implant
Insures controlled product release over time
Avoids "peak and valley" effects
Guarantees consistent product preparation
Extends product life against spontaneous breakdown
Extends product life against host-related breakdown
Minimizes experimental variables
Insures safety of the experimenter
Reduces neurophysiological trauma to animal/no excessive handling
Generates more meaningful and reproducible results
Superior to conventional delivery methods
Enhances experimental efficiency
Frees valuable time for creative research
Saves money
Innovative Research of America的主要产品包括:
ANTIBIOTICS
ANTI-INFLAMMATORY AGENTS
ANTI-NEOPLASTICS
CATECHOLAMINES & RELATED PRODUCTS
CORTICOIDS & DIURETICS
ESTROGENS & ANTI-ESTROGENS
FATTY ACIDS
MISCELLANEOUS PRODUCTS
NUCLEOTIDE RELATED PRODUCTS
PLACEBO
PROGESTINS
PROSTAGLANDINS
THYROIDS
VITAMINS
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Innovative Research of America"> Innovative Research of America
Cygnus Technologies是一家专为基因工程生物制药企业、疫苗生产企业、学术研究、生物制药研发部门和QA部门(品质保证部门)提供宿主细胞蛋白残留检测和生物制药工程中污染物的残留检测技术和产品的公司。美国Cygnus公司提供了种类广泛而灵敏度极高的一系列用于检测宿主蛋白残留物的HCP ELISA试剂盒和BC ELISA试剂盒等产品,
We offer a comprehensive menu of well-validated, convenient to use microtiter plate ELISA methods to detect Host Cell Proteins from specific recombinant expression systems and bioprocess contaminants used in culture media as well as transgenic expression systems in goats and cattle. We develop and routinely manufacture, by cGMP methods, ELISA and Western Blot kits to contaminants specific to more than 50 different expression systems. Our extensive list of ancillary reagents is useful in developing and validating your product and process-specific assays.
Cygnus Technologies公司的主要产品包括:
ELISA Kits
DNA Detection
Western Blot Kits
Antibodies
Immunogenicity Analysis
Antigen Concentrates
Immunoassay Reagents
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Cygnus Technologies"> Cygnus Technologies
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://gerbu.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:17754422825
传真:18771997407
邮箱:sales@amyjet.com
0.322